Log in to search using one of your social media accounts:

 

Pulmatrix doses first patient in Ph1 Pulmazole trial

Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole. The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Related Links:

This study, we described 10 patients (6 male and 4 female) with SCID who were admitted to Mofid Children Hospital, Tehran, Iran, from 2006 to 2013. We reviewed patients' clinical manifestation, laboratory data, family history and outcome. The mean age at the time of diagnosis was 131.8 days. One patient had non-consanguineous parents. Seven patients received BCG vaccine before the diagnosis of SCID, three of them showed disseminated BCG infection. One patient presented with invasive pulmonary aspergillosis. Flow cytometric analysis showed T⁻B⁺NK⁻ in three patients, T⁻B⁻NK⁺ in five patients, T⁻B⁻NK⁻ in one...
Source: Iranian Journal of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Iran J Allergy Asthma Immunol Source Type: research
Mycoses, EarlyView.
Source: Mycoses - Category: Research Source Type: research
CONCLUSIONS: There is lack of evidence for the efficacy and safety of anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis. There is a need for large prospective randomized controlled studies of anti-IgE therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis with both clinical and laboratory outcome measures such as steroid requirement, allergic bronchopulmonary aspergillosis exacerbations and lung function. PMID: 29551015 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
AbstractAsthma is an allergic, respiratory disorder characterized by hyper responsiveness of the airway to external stimuli. Considerable research is currently being directed towards understanding the role of environmental and genetic factors contributing to the development of asthma and its severity. Recent years have seen a substantial rise in evidence linking fungi to asthma. Few major clinical conditions associated with fungal sensitization and hypersensitive immune response are Allergic bronchopulmonary aspergillosis (ABPA), Allergic fungal rhinosinusitis (AFRS) and Severe asthma with fungal sensitization (SAFS). The ...
Source: Indian Journal of Pediatrics - Category: Pediatrics Source Type: research
BLACK mould and damp is a common problem during this time of year and respiratory problems, allergies, and asthma can be a result of infestations. Inhaling tiny bits of mould can also cause a condition called aspergillosis. The NHS explains how best to get rid of mould and damp problems.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
This study was conducted to know the correlation of AH with severity and duration of asthma. Patients, age>15 years, of asthma attending this hospital from January 2015 to December 2015 were included. Asthma was diagnosed clinically and confirmed with spirometry. Of 282 patients 206 patients were AH positive. The AST-positivity in patients having severe asthma (96.8%) was higher than that in patients having mild (36.8%) and moderate asthma (80.4%). The median (IQR) duration of asthma of AH positive patients was 5.0 yrs. This study emphasized the need of ABPA screening by intradermal skin test especially in patients havi...
Source: Monaldi Archives for Chest Disease - Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research
Authors: Jeong JS, Kim SR, Lee YC Abstract Severe asthma is a heterogeneous disease entity to which diverse cellular components and pathogenetic mechanisms contribute. Current asthma therapies, including new biologic agents, are mainly targeting T helper type 2 cell-dominant inflammation, so that they are often unsatisfactory in the treatment of severe asthma. Respiratory fungal exposure has long been regarded as a precipitating factor for severe asthma phenotype. Moreover, as seen in clinical definitions of allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS), fungal al...
Source: Allergy, Asthma and Immunology Research - Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research
Many patients with severe persistent asthma have evidence of both Th2 and eosinophilic inflammation. This is often seen in ABPA with IgE levels>1000 U/mL and peripheral eosinophil counts>500 cells/mL, however, can also be seen without aspergillus sensitization. The optimal approach to steroid-sparing biologic therapy in such patients is unclear, and many continue to have active disease after a single biologic therapy is initiated.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
The UK Medicines and Healthcare Products Regulatory Agency has given Pulmatrix (NSDQ:PULM) the go-ahead to launch its first-in-human study for an inhaled formulation of the anti-fungal drug, itraconazole. The company is evaluating its drug, Pulmazole, as a treatment for allergic bronchopulmonary aspergillosis in patients with asthma. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news
Abstract BACKGROUND AND AIMS: Whether itraconazole monotherapy is effective in the acute-stage of allergic bronchopulmonary aspergillosis (ABPA) remains unknown. Herein, we compare the efficacy and safety of itraconazole and prednisolone monotherapy in ABPA. METHODS: We randomized treatment-naïve subjects with ABPA complicating asthma (January 2012 to December 2013) to receive either oral itraconazole or prednisolone for four months. The study was not blinded. The primary outcomes were proportion of subjects showing composite response after six weeks, percentage decline in IgE after treatment, and number...
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
More News: Allergy & Immunology | Aspergillosis | Asthma | Clinical Trials | Respiratory Medicine | Study